United States · FDA National Drug Code directory
OMLYCLO
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 72606-054_89c265ef-7a29-46f4-aaa1-88ab318e30b9
- Product NDC
- 72606-054
- Form
- INJECTION
- Composition / generic term
- omalizumab-igec
- Labeler
- CELLTRION USA, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20260901
- Source listing expiry
- 20271231
Source-listed ingredients
- OMALIZUMAB — 300 mg/2mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 SYRINGE, GLASS in 1 CARTON (72606-054-01) / 2 mL in 1 SYRINGE, GLASS · 72606-054-01
- 2 SYRINGE, GLASS in 1 CARTON (72606-054-02) / 2 mL in 1 SYRINGE, GLASS · 72606-054-02
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →